Maravai LifeSciences (MRVI) Q4 2025 earnings summary

Executive summary

• Achieved full-year 2025 revenue of $185.7 million and Q4 revenue of $49.9 million, returning to positive adjusted EBITDA in Q4 at $0.5 million after several loss quarters.

• Cost savings from restructuring exceeded $65 million annualized, well above the initial $50 million target, supporting improved operational efficiency.

• TriLink segment drove growth in GMP consumables and CDMO, while Cygnus growth was led by core customers and HCP kits.

• Enhanced commercial execution, customer engagement, and operational efficiency, positioning for revenue growth and profitability in 2026.

• Strong order volume and increased visibility, with a robust pipeline of new products and services.

Financial highlights

• Q4 revenue: $49.9 million; full-year revenue: $185.7 million; Q4 adjusted EBITDA: $0.5 million; full-year adjusted EBITDA: -$31.2 million.

• Q4 GAAP net loss: $63 million; full-year GAAP net loss: $230.8 million.

• Q4 adjusted EPS loss: $0.04; full-year adjusted EPS loss: $0.29.

• Ended year with $216.9 million cash and $294.2 million long-term debt; net cash of $(77.3) million.

• Q4 cash used in operations: $22.8 million; depreciation/amortization: $12.4 million; net interest expense: $4.2 million.

Outlook and guidance

• 2026 revenue expected at $200–$210 million (8–13% growth over 2025); adjusted EBITDA guidance: $18–$20 million.

• Gross margin expansion of ~1,200 basis points; operating expenses to decline 13%, G&A down 18%, sales/marketing down 13%, R&D modestly up.

• TriLink to grow low double digits, Cygnus low to mid single digits.

• COVID CleanCap revenue of $10–$20 million expected in H1 2026 only.

• Interest expense forecasted at $15–$17 million; depreciation/amortization at $50–$52 million; net capital expenditures $4–$6 million.